[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fPBR8HT3C5iSgb2NUaS7UWSc3y4OT4glHhT3YvfmL3b0":8,"$f_wzf1TPQJyIh38IsPs_71AG2ilppG5CoPUrPma35B98":56,"$fUzGbMxY9sZD4aS7-r1FSwV1BgbIhOdL4AC0J7XA16pY":60},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":55},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":29,"seoKeywords":30,"seoDescription":31,"shelvesTime":32,"version":33,"menus":34,"menuId":36,"type":43,"quality":54,"commentCount":21,"isComment":43},68427,868808,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//iTCP1DSvplAFJhNCT6SR8jINhAgp8TZa.png","王凯来","浙江大学医学院附属第二医院","肿瘤科","住院医师",20,0,"01. 免疫与靶向药：常见成分及剂型规格","","https://ystcdn.venuertc.com/venue/AI/47c70783-a445-48d2-b2ac-efba1edcf849.jpg","\u003Cdiv class=\"oncology_drug_material\">\n  \u003Ch1 id=\"material_title\" class=\"oncology_drug_title\">结肠癌术后复发用药安全指南：详解免疫与靶向药物合理使用\u003C/h1>\n  \u003Cdiv class=\"oncology_drug_intro\">\n    \u003Cp>聊到结肠癌术后复发，大家常听说免疫治疗和靶向药。其实，这两类药物已经成为结肠肿瘤治疗中不可或缺的选择。它们各自有独特的作用方式，但在具体使用上需要关注的细节也不少。今天我们用最实用的方式，详细梳理\u003Cstrong>7大关键用药要点\u003C/strong>，帮你学会安全合理地用好这些药物。🩺\u003C/p>\n  \u003C/div>\n  \u003C!-- 01 药品成分与剂型规格 -->\n  \u003Csection class=\"oncology_drug_section oncology_drug_bg1\">\n    \u003Ch2>01. 免疫与靶向药：常见成分及剂型规格\u003C/h2>\n    \u003Cul class=\"oncology_drug_list\">\n      \u003Cli>目前结肠癌术后常用的免疫药，主要为PD-1/PD-L1抑制剂，如帕博利珠单抗、纳武利尤单抗等，属于单克隆抗体，大多制成注射液。\u003C/li>\n      \u003Cli>抗血管生成类靶向药，包括贝伐珠单抗、阿柏西普等，通常为静脉注射型制剂。\u003C/li>\n      \u003Cli>部分小分子靶向药，如瑞戈非尼，往是口服片剂，规格有40mg、80mg、120mg等。\u003C/li>\n      \u003Cli>剂型选择直接影响服药方案。注射药需要医疗机构操作，口服药需遵医嘱自行服用。\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"oncology_drug_tip\">💡正确做法：用药前仔细核对成分名称和规格，避免混淆。每种药品的说明书里都明确写有剂型与规格，取药时务必再次确认。\u003C/div>\n  \u003C/section>\n\n  \u003C!-- 02 作用机制简单说明 -->\n  \u003Csection class=\"oncology_drug_section oncology_drug_bg2\">\n    \u003Ch2>02. 免疫与靶向药的作用机理到底怎么不一样？\u003C/h2>\n    \u003Cul class=\"oncology_drug_list\">\n      \u003Cli>\u003Cstrong>PD-1/PD-L1抑制剂\u003C/strong>：通过解除肿瘤对免疫系统的抑制，激活体内T细胞对异常组织的识别与清除。\u003C/li>\n      \u003Cli>\u003Cstrong>抗血管生成药\u003C/strong>：阻断肿瘤新生血管的生成，使异常组织\"断粮\"，从而抑制其扩展。\u003C/li>\n      \u003Cli>\u003Cstrong>小分子靶向药\u003C/strong>：通过抑制关键的信号转导酶系，阻止异常细胞生长分裂。\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"oncology_drug_tip\">需要注意：免疫药与靶向药尽管用于同类治疗，但实际的作业路径完全不同，联用时可产生协同作用，但需严密监测。\u003C/div>\n  \u003C/section>\n\n  \u003C!-- 03 服用时间与方法：细节决定疗效 -->\n  \u003Csection class=\"oncology_drug_section oncology_drug_bg3\">\n    \u003Ch2>03. 服用时间和方法：每一细节都很关键\u003C/h2>\n    \u003Cul class=\"oncology_drug_list\">\n      \u003Cli>\u003Cstrong>注射型免疫和靶向药\u003C/strong>：通常按照固定周期在医院由医生操作，不能自行注射。\u003C/li>\n      \u003Cli>\u003Cstrong>口服型靶向药\u003C/strong>（如瑞戈非尼）：需整片吞服，不能嚼碎，可用一杯温水送服。\u003C/li>\n      \u003Cli>如说明书无特殊要求，建议每天同一时段服药，有些药需餐后服用以降低胃肠刺激。\u003C/li>\n      \u003Cli>注射药每次使用前须检查溶液是否澄清，有无异物及变色。\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"oncology_drug_tip\">正确做法：一旦到服药（或注射）时间，不要自行更改用药次数或剂量，遇到特殊情况向医生咨询。\u003C/div>\n  \u003C/section>\n\n  \u003C!-- 04 剂量调整与特殊人群用药 -->\n  \u003Csection class=\"oncology_drug_section oncology_drug_bg4\">\n    \u003Ch2>04. 剂量选择与特殊人群：不能“一刀切”\u003C/h2>\n    \u003Cul class=\"oncology_drug_list\">\n      \u003Cli>常规剂量依据体重或体表面积精确计算，尤其是注射型药物。\u003C/li>\n      \u003Cli>老年患者、新陈代谢较差、身体体能减退时，医生会适当下调剂量，减少风险。\u003C/li>\n      \u003Cli>肝肾功能不全者需高度重视用量调整，小分子靶向药尤其要规范。\u003C/li>\n      \u003Cli>孕妇和哺乳期女性通常不推荐使用此类药物，如需用药须评估风险与获益。\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"oncology_drug_tip\">自我调整剂量风险大。比如，一位63岁的男性患者在接受免疫与抗血管生成靶向药联合用药过程中，因听信外界说法自行减少剂量，结果疗效受影响。所以剂量调整一定要和专科医生沟通。\u003C/div>\n  \u003C/section>\n\n  \u003C!-- 05 禁忌与安全边界 -->\n  \u003Csection class=\"oncology_drug_section oncology_drug_bg5\">\n    \u003Ch2>05. 用药禁忌：必须避开的风险红线\u003C/h2>\n    \u003Cul class=\"oncology_drug_list\">\n      \u003Cli>已知对蛋白制剂或药物成分过敏者绝对禁止使用。\u003C/li>\n      \u003Cli>存在严重活动性感染、免疫缺陷的人群，免疫药物应慎用。\u003C/li>\n      \u003Cli>严重未控制的高血压或出血倾向，不宜使用抗血管生成类靶向药物。\u003C/li>\n      \u003Cli>近期行重大外科手术、未愈合伤口，应暂缓抗血管生成药使用。\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"oncology_drug_tip\">特别提醒：发现过敏症状，应立即停止用药并及时就医处理。对于免疫类药物，既往免疫系统疾病史必须告知医生。\u003C/div>\n  \u003C/section>\n\n  \u003C!-- 06 药物相互作用详解 -->\n  \u003Csection class=\"oncology_drug_section oncology_drug_bg6\">\n    \u003Ch2>06. 药物相互作用：这些药绝不能随便一起用\u003C/h2>\n    \u003Cul class=\"oncology_drug_list\">\n      \u003Cli>小分子靶向药（如瑞戈非尼）与酮康唑等强效CYP3A4酶抑制剂合用时，血药浓度会升高，增加毒性风险。\u003C/li>\n      \u003Cli>大部分免疫检查点抑制剂同活疫苗同时使用可增加副作用风险，避免合用。\u003C/li>\n      \u003Cli>抗血管生成药（如贝伐珠单抗）与抗凝药并用，有出血倾向时要特别小心。\u003C/li>\n      \u003Cli>联用其他肿瘤治疗药物须由医生评估相互作用后决定。\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"oncology_drug_tip\">正确做法：告知医生近期所有用药，各种补品和中药也别遗漏。有疑问时查询药品说明书，了解是否有已知重要相互作用。\u003C/div>\n  \u003C/section>\n\n  \u003C!-- 07 可能不良反应和应对方式 -->\n  \u003Csection class=\"oncology_drug_section oncology_drug_bg7\">\n    \u003Ch2>07. 常见不良反应与处理技巧\u003C/h2>\n    \u003Cul class=\"oncology_drug_list\">\n      \u003Cli>免疫药物常见不良反应有皮疹、乏力、肌肉痛、内分泌失调等。\u003C/li>\n      \u003Cli>靶向药如瑞戈非尼可引起手足皮肤反应、高血压、蛋白尿等。\u003C/li>\n      \u003Cli>抗血管生成类药物则有出血、延迟创面愈合、血压升高等风险。\u003C/li>\n      \u003Cli>如出现持续发热、黄疸、皮肤严重瘙痒等，需及时就诊。\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"oncology_drug_tip\">出现轻微皮疹时可使用低敏润肤剂辅助护理。任何严重反应务必及时报告医生，根据反应具体情况调整用药。\u003C/div>\n    \u003Cdiv class=\"oncology_drug_data\">🌡️ 临床数据显示，免疫相关的不良反应整体发生率约12-20%，重度反应少见，但应高度警惕（Sharma, P. et al., 2017）。\u003C/div>\n  \u003C/section>\n\n  \u003C!-- 08 药物储存与管理 -->\n  \u003Csection class=\"oncology_drug_section oncology_drug_bg8\">\n    \u003Ch2>08. 储存和妥善管理药品的关键操作\u003C/h2>\n    \u003Cul class=\"oncology_drug_list\">\n      \u003Cli>绝大多数免疫单抗和抗血管生成类注射剂需要冷藏，建议2-8℃密闭避光储存。\u003C/li>\n      \u003Cli>口服小分子靶向药应避光、干燥、室温（<25℃）保存，远离儿童。\u003C/li>\n      \u003Cli>药品开封后，应尽快使用，剩余药物应按说明弃置，切勿自行处理。\u003C/li>\n      \u003Cli>瓶装注射液如发现药液浑浊或有沉淀，应废弃不用。\u003C/li>\n      \u003Cli>过期药品禁止服用，可交由专业机构统一回收。\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"oncology_drug_tip\">实际生活中，有患者因冰箱温度太低将药液冻住，造成药效失灵。冷藏药品时注意用专用温度计监控温度。\u003C/div>\n  \u003C/section>\n\n  \u003C!-- 09 漏服与过量应对 -->\n  \u003Csection class=\"oncology_drug_section oncology_drug_bg9\">\n    \u003Ch2>09. 遇到漏服与过量：如何处理最妥当？\u003C/h2>\n    \u003Cul class=\"oncology_drug_list\">\n      \u003Cli>如漏服口服药物，建议尽早补服一次，但切勿一次服用双倍剂量。\u003C/li>\n      \u003Cli>注射药如果错过预约时间，不要自行补打，需重新预约医生管理。\u003C/li>\n      \u003Cli>不慎过量服药，须立即停止服用并尽快至医院接受专业处理。\u003C/li>\n      \u003Cli>药物过量时，部分药物有特定解毒药，具体处理方式以医院决定为主。\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"oncology_drug_tip\">⚠️ 保持冷静，记录具体漏服或过量时间与剂量，带上药品包装就医。\u003C/div>\n  \u003C/section>\n\n  \u003C!-- 10 高发用药误区盘点 -->\n  \u003Csection class=\"oncology_drug_section oncology_drug_bg10\">\n    \u003Ch2>10. 用药误区与处理经验\u003C/h2>\n    \u003Col class=\"oncology_drug_mistakes\">\n      \u003Cli>有患者为减轻副作用，自行停止用药，导致疗效中断。\u003C/li>\n      \u003Cli>部分人忽略肝肾功能变化，未定期监测血压与尿检。\u003C/li>\n      \u003Cli>混淆不同制剂规格，错用剂量，影响药效。\u003C/li>\n      \u003Cli>冷藏药品随意放在冷冻层导致变质失效。\u003C/li>\n    \u003C/ol>\n    \u003Cdiv class=\"oncology_drug_tip\">用药过程中遇到困惑，可随时带着药盒包装向药师或医生咨询。\u003C/div>\n  \u003C/section>\n\n  \u003C!-- 引用文献 -->\n  \u003Csection class=\"oncology_drug_section oncology_drug_bgref\">\n    \u003Ch2>主要参考文献\u003C/h2>\n    \u003Col class=\"oncology_drug_reference\">\n      \u003Cli>\u003Cspan class=\"oncology_drug_ref_title\">Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A.\u003C/span> (2017). Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. \u003Cem>Cell\u003C/em>, 168(4), 707–723. https://doi.org/10.1016/j.cell.2017.01.017\u003C/li>\n      \u003Cli>\u003Cspan class=\"oncology_drug_ref_title\">Tabernero, J. et al.\u003C/span> (2015). Regorafenib for metastatic colorectal cancer: results of a phase III study. \u003Cem>The Lancet\u003C/em> 381(9863): 303-312. https://doi.org/10.1016/S0140-6736(12)61900-X\u003C/li>\n      \u003Cli>\u003Cspan class=\"oncology_drug_ref_title\">National Comprehensive Cancer Network (NCCN)\u003C/span>. (2024). NCCN Guidelines for Colon Cancer. https://www.nccn.org/guidelines\u003C/li>\n      \u003Cli>\u003Cspan class=\"oncology_drug_ref_title\">Li, J., Qin, S., Xu, R. et al.\u003C/span> (2016). Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. \u003Cem>The Lancet Oncology\u003C/em>, 16(6), 619-629. https://doi.org/10.1016/S1470-2045(15)70156-7\u003C/li>\u003C/ol>\u003C/section>\n\u003C/div>\n\n\u003Cstyle>\n/* 独立命名全局样式，防止干扰页面其他内容 */\n.oncology_drug_material {\n  font-family: 'Segoe UI', Arial, 'PingFang SC', 'Hiragino Sans GB', 'Microsoft YaHei', sans-serif;\n  max-width: 900px;\n  margin: 32px auto;\n  background: #f6f9fa;\n  border-radius: 18px;\n  box-shadow: 0 4px 24px #e1e7ec;\n  padding: 38px 36px 38px 36px;\n}\n.oncology_drug_title {\n  font-size: 2.3em;\n  color: #163859;\n  text-align: center;\n  margin-bottom: 26px;\n  letter-spacing: 2px;\n}\n.oncology_drug_intro {\n  font-size: 1.16em;\n  color: #264050;\n  background: linear-gradient(92deg, #ecf7fe 60%, #f6f9fa 100%);\n  border-left: 5px solid #44bacc;\n  padding: 18px 20px;\n  border-radius: 10px;\n  margin-bottom: 32px;\n}\n.oncology_drug_section {\n  margin-bottom: 34px;\n  padding: 24px 26px;\n  border-radius: 13px;\n  position: relative;\n  box-sizing: border-box;\n  min-height: 60px;\n  border-left: 6px solid #47c2a2;\n}\n\n/* 每个section的淡雅背景渐变区分 */\n.oncology_drug_bg1 { background: linear-gradient(80deg, #f3fcfa 70%,#f8f8ff 100%); border-color: #48b6d2;}\n.oncology_drug_bg2 { background: linear-gradient(85deg, #f8fbf0 60%,#eff6fa 100%); border-color: #b8e26d;}\n.oncology_drug_bg3 { background: linear-gradient(80deg, #fdfaf5 60%,#f6fafe 100%); border-color: #f6c177;}\n.oncology_drug_bg4 { background: linear-gradient(85deg, #f7f7fc 50%,#eaf2 100%); border-color: #65d1ae;}\n.oncology_drug_bg5 { background: linear-gradient(75deg, #fcf7f7 60%,#f8f9fe 100%); border-color: #f07286;}\n.oncology_drug_bg6 { background: linear-gradient(88deg, #eef7fc 40%,#e7fff3 97%); border-color: #6bb4df;}\n.oncology_drug_bg7 { background: linear-gradient(82deg, #fafcf4 90%,#f0f5f7 100%); border-color: #b7cf65;}\n.oncology_drug_bg8 { background: linear-gradient(60deg, #f7fafd 60%,#f7fefb 100%); border-color: #77c7f7;}\n.oncology_drug_bg9 { background: linear-gradient(88deg, #fef8f8 75%,#f5f9ff 100%); border-color: #f1a366;}\n.oncology_drug_bg10{ background: linear-gradient(82deg, #f5f5fd 40%,#f8fafc 90%); border-color: #47b7ac;}\n.oncology_drug_bgref{ background: linear-gradient(80deg, #f4fcff 80%,#f7f7fa 100%); border-color: #b3c5d1; }\n\n.oncology_drug_section h2 {\n  font-size: 1.33em;\n  font-weight: 600;\n  color: #307494;\n  margin-bottom: 18px;\n  letter-spacing: 1px;\n  line-height: 1.32em;\n}\n.oncology_drug_list {\n  padding-left: 22px;\n  margin-bottom: 10px;\n  color: #2f4150;\n  font-size: 1.08em;\n}\n.oncology_drug_list li {\n  margin-bottom: 9px;\n  line-height: 1.7em;\n  list-style-type: disc;\n}\n.oncology_drug_tip {\n  margin-top: 10px;\n  background: #e4f5f8;\n  color: #4b8397;\n  border-left: 4px solid #3fc2c3;\n  border-radius: 5px;\n  padding: 11px 15px;\n  font-size: 1em;\n}\n.oncology_drug_data {\n  margin-top: 7px;\n  background: #f9f2e9;\n  color: #ad7c02;\n  border-left: 4px solid #f6c177;\n  border-radius: 7px;\n  padding: 10px 14px;\n  font-size: 0.97em;\n}\n.oncology_drug_mistakes {\n  color: #5d5a7d;\n  font-size: 1.06em;\n  padding-left: 25px;\n  margin-bottom: 12px;\n}\n.oncology_drug_mistakes li {\n  margin-bottom: 7px;\n}\n.oncology_drug_reference {\n  font-size: 0.98em;\n  color: #4d6483;\n  padding-left: 17px;\n  margin-bottom: 8px;\n}\n.oncology_drug_ref_title { font-weight:600; color:#17567c; }\n\n.oncology_drug_conclusion {\n  background: #f8f7ef;\n  border-left: 5px solid #cfc080;\n  margin-top:36px;\n  padding: 14px 20px;\n  border-radius: 9px;\n  color: #70663d;\n  font-size: 1.08em;\n  text-align: center;\n}\n@media screen and (max-width: 700px) {\n  .oncology_drug_material {padding: 10px 2vw;}\n  .oncology_drug_title {font-size: 1.5em;}\n  .oncology_drug_section { padding: 17px 7px;}\n}\n\u003C/style>","\u003Cdiv class=\"oncology_drug_material\">\n  \u003Ch1 id=\"material_title\" class=\"oncology_drug_title\">结肠癌术后复发用药",548,"2025-10-24 00:17:22","结肠癌术后复发用药安全指南：详解免疫与靶向药物合理使用","结肠癌, 免疫治疗, 靶向药物, 用药安全, 药物副作用","了解结肠癌术后复发患者如何安全合理使用免疫和靶向药物，避免误区，并掌握关键用药要点，提升治疗效果。","2025-11-10 12:02:23",2,[35],{"menuId":36,"menuName":37,"parentId":21,"orderNum":33,"path":38,"component":39,"isFrame":40,"isCache":41,"menuType":42,"visible":43,"status":21,"createDept":6,"remark":23,"createTime":44,"children":45,"columnImage":46,"columnLogo":47,"uncheckedLogo":6,"checkedLogo":6,"isHot":43,"isHome":21,"forceLogin":21,"color":48,"seoTitle":49,"seoKeywords":50,"seoDescription":51,"contentNum":6,"promotionalPoster":52,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":53,"routerPath":38,"componentInfo":39},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":57,"success":55},{"pageNo":43,"pageSize":58,"result":59,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":61,"success":55},{"authors":62,"appraiseDimensionScoresVos":63},[],[]]